Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 4001 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 26 |
| 4002 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 56 |
| 4003 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 63 |
| 4004 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 61 |
| 4005 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 70 |
| 4006 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 66 |
| 4007 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Germany | 48 |
| 4008 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Germany | 58 |
| 4009 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Germany | 59 |
| 4010 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 62 |
| 4011 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 63 |
| 4012 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 4013 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 66 |
| 4014 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 65 |
| 4015 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 56 |
| 4016 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2021 | Standard Therapy | Poland | 75 |
| 4017 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2021 | Standard Therapy | Poland | 65 |
| 4018 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2021 | Standard Therapy | Poland | 51 |
| 4019 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2021 | Standard Therapy | Poland | 63 |
| 4020 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2021 | Standard Therapy | Poland | 75 |
| 4021 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 4022 | Apheresis | Allogeneic | Myeloma Multiplex | Hematology | 2021 | Standard Therapy | Poland | 48 |
| 4023 | Apheresis | Allogeneic | Myeloma Multiplex | Hematology | 2021 | Standard Therapy | Poland | 53 |
| 4024 | Apheresis | Allogeneic | Myeloproliferative Neoplasms | Hematology | 2021 | Standard Therapy | Poland | 67 |
| 4025 | Apheresis | Allogeneic | Myeloproliferative Neoplasms | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 4026 | Apheresis | Allogeneic | Myeloproliferative Neoplasms | Hematology | 2021 | Standard Therapy | Germany | 51 |
| 4027 | Apheresis | Allogeneic | No Data | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 4028 | Apheresis | Allogeneic | No Data | Hematology | 2021 | Standard Therapy | Poland | 57 |
| 4029 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 30 |
| 4030 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 51 |
| 4031 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 4032 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 56 |
| 4033 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 4034 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 50 |
| 4035 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 53 |
| 4036 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 20 |
| 4037 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 4038 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 66 |
| 4039 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 62 |
| 4040 | Apheresis | Autologous | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 61 |
| 4041 | Apheresis | Autologous | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 49 |
| 4042 | Apheresis | Allogeneic | Non-Hodgkin-Lymphoma-Relapse | Hematology | 2021 | Standard Therapy | Germany | 62 |
| 4043 | Apheresis | Allogeneic | Osteomyelitis | Hematology | 2021 | Standard Therapy | Poland | 47 |
| 4044 | Apheresis | Allogeneic | Osteomyelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 69 |
| 4045 | Apheresis | Allogeneic | Osteomyelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 43 |
| 4046 | Apheresis | Autologous | Osteosclerotic Myeloma | Hematology | 2021 | Standard Therapy | Germany | 54 |
| 4047 | Apheresis | Allogeneic | Other Myelodysplastic Syndromes | Hematology | 2021 | Standard Therapy | Poland | 65 |
| 4048 | Apheresis | Allogeneic | Other Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 68 |
| 4049 | Apheresis | Allogeneic | Other Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 70 |
| 4050 | Apheresis | Allogeneic | Other Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 72 |
| 4051 | Apheresis | Allogeneic | Other Plasma Cell Disorder | Hematology | 2021 | Standard Therapy | Poland | 67 |
| 4052 | Apheresis | Allogeneic | Peripheral T-Cell Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 45 |
| 4053 | Apheresis | Allogeneic | Philadelphia-Positive Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 61 |
| 4054 | Apheresis | Allogeneic | Polycythemia Vera | Hematology | 2021 | Standard Therapy | Poland | 65 |
| 4055 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 71 |
| 4056 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 66 |
| 4057 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 62 |
| 4058 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 53 |
| 4059 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 44 |
| 4060 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 54 |
| 4061 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 65 |
| 4062 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 65 |
| 4063 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 60 |
| 4064 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 66 |
| 4065 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 63 |
| 4066 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 62 |
| 4067 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 4068 | Apheresis | Allogeneic | Prolymphocytic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 68 |
| 4069 | Apheresis | Allogeneic | Prolymphocytic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 4070 | Apheresis | Allogeneic | Refractory Cytopenia | Hematology | 2021 | Standard Therapy | Poland | 6 |
| 4071 | Apheresis | Allogeneic | Secondary Acute Lymphoblastic Leukemia From Chronic Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 4072 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Germany | 70 |
| 4073 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Germany | 64 |
| 4074 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Germany | 39 |
| 4075 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Germany | 60 |
| 4076 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 35 |
| 4077 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 4078 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 41 |
| 4079 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 38 |
| 4080 | Apheresis | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2021 | Standard Therapy | Poland | 1 |
| 4081 | Apheresis | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2021 | Standard Therapy | Poland | 1 |
| 4082 | Apheresis | Allogeneic | T-Cell Lymphoblastic Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 26 |
| 4083 | Apheresis | Allogeneic | T-Cell Lymphoblastic Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 37 |
| 4084 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 54 |
| 4085 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 66 |
| 4086 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 66 |
| 4087 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 29 |
| 4088 | Apheresis | Allogeneic | T-Cell-Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 45 |
| 4089 | Apheresis | Autologous | Testicular Cancer | Hematology | 2021 | Standard Therapy | Germany | 33 |
| 4090 | Apheresis | Allogeneic | Β – Thalassemia | Hematology | 2021 | Standard Therapy | Poland | 17 |
| 4091 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2021 | Experimental Therapy | Poland | 51 |
| 4092 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2021 | Experimental Therapy | Poland | 44 |
| 4093 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2021 | Experimental Therapy | Poland | 35 |
| 4094 | Adipose Tissue | Autologous | Internal Damage To The Knee Joint | Orthopedy | 2021 | Experimental Therapy | Poland | 41 |
| 4095 | Adipose Tissue | Autologous | Soft Tissue Diseases Related To Use, Overload And Pressure | Orthopedy | 2021 | Experimental Therapy | Poland | 27 |
| 4096 | Placenta blood | Autologous | Cerebral Palsy | Neurology | 2020 | Experimental Therapy | Poland | 2 |
| 4097 | Cord Tissue | Allogeneic – Unrelated | Covid-19 | Pulmonology | 2020 | Experimental Therapy | Poland | 84 |
| 4098 | Cord Tissue | Allogeneic – Unrelated | Acquired Epileptic Aphasia | Neurology | 2020 | Experimental Therapy | Poland | 4 |
| 4099 | Cord Tissue | Allogeneic – Unrelated | Acute Graft Versus Host Disease | Hematology | 2020 | Experimental Therapy | Poland | 8 |
| 4100 | Cord Tissue | Allogeneic – Unrelated | Acute Graft Versus Host Disease | Hematology | 2020 | Experimental Therapy | Poland | 8 |